Protein–protein interactions (PPIs) govern all biological processes. Some small molecules
modulate PPIs through induced protein proximity. In particular, molecular glue degraders …

In recent years, proteolysis-targeting chimeras (PROTACs), capable of achieving targeted
protein degradation, have proven their great therapeutic potential and usefulness as …

Targeted protein degradation (TPD) mediates protein level through small molecule induced
redirection of E3 ligases to ubiquitinate neo-substrates and mark them for proteasomal …

Targeted protein degradation (TPD) is a rapidly developing field in chemical biology and
drug discovery. Various TPD modalities have emerged, with proteolysis-targeting chimeras …

PROteolysis TArgeting Chimera (PROTAC) is an emerging technology in chemical biology
and drug discovery. This technique facilitates the complete removal of the target proteins …

A missense variant in patatin-like phospholipase domain-containing protein 3 [PNPLA3
(I148M)] is the most impactful genetic risk factor for fatty liver disease (FLD). We previously …

Targeted protein degradation (TPD) of neo-substrates with proteolysis targeting chimeras
(PROTACs) or molecular glues has emerged as a key modality in exploring new biology as …

We report targeted protein degradation through the site-specific recruitment of native
ubiquitin ligases to a protein of interest via conjugation of E3 ligase ligands. Direct …

Targeting E3 ligases is a challenging area in drug discovery. Despite the human genome
encoding for more than 600 E3 ubiquitin ligases, only a handful of E3 ligases have been …

One of the major challenges in evaluating the suitability of potential~ 700 E3 ligases for
target protein degradation (TPD) is the lack of binders specific to each E3 ligase. Here we …